For US Healthcare Professionals Only
Indolent ISMAdvanced SMPDGFRA GIST
  About ISM  
  About AYVAKIT  
  Efficacy  

  Safety  
  Dosing  
  Resources  
Indolent ISMAdvanced SMPDGFRA GIST

SELECT A CONDITION

ISM

Indolent systemic mastocytosis (ISM)

AdvSM

Advanced systemic mastocytosis (AdvSM)

PDGFRA
GIST

Gastrointestinal stromal tumors with PDGFRA mutation (PDGFRA GIST)

AYVAKIT® (avapritinib) 25 mg white logo

The FIRST and ONLY therapy approved for the treatment of adults with indolent systemic mastocytosis (ISM)1

Designed for potent and selective inhibition of KIT D816V, the primary driver of disease in ~95% of patients1-4

See efficacy data from the PIONEER clinical trial1
Efficacy
Explore the safety of AYVAKIT for ISM1
Safety
Access additional resources for you and your patients
Resources
With AYVAKIT, your patients have access to the YourBlueprint® patient support program. Enrollment is quick and easy.
Enroll Your Patients

Sign up to receive updates on AYVAKIT for ISM and connect with a representative

All fields required unless otherwise noted.

By submitting this form:

  • I confirm that I am a US healthcare professional and agree to receive information about AYVAKIT for ISM and related disease state information. I can opt out from such communications by replying “Unsubscribe” to any email.
  • I acknowledge that I have read and agree to Blueprint Medicines' Terms of Use.

To learn more about Blueprint Medicines' privacy practices, including how we process, share, and protect your Personal Information, please read our Privacy Notice.

Oops! We're missing key information we need to connect with you.

Submit
Expand +
INDICATION

AYVAKIT® (avapritinib) is indicated for the treatment of adult patients with indolent systemic mastocytosis (ISM).

Limitations of Use: AYVAKIT is not recommended for the treatment of patients with ISM with platelet counts of <50 x 109/L.

IMPORTANT SAFETY INFORMATION
INDICATION & IMPORTANT SAFETY INFORMATION

Intracranial Hemorrhage (ICH)—Serious ICH may occur with AYVAKIT treatment; fatal events occurred in <1% of patients. No events of ICH occurred in the 246 patients with ISM who received any dose of AYVAKIT in the PIONEER study.

Monitor patients closely for risk factors of ICH which may include history of vascular aneurysm, ICH or cerebrovascular accident within the prior year, concomitant use of anticoagulant drugs, or thrombocytopenia.

Symptoms of ICH may include headache, nausea, vomiting, vision changes, or altered mental status. Advise patients to seek immediate medical attention for signs or symptoms of ICH.

Permanently discontinue AYVAKIT if ICH of any grade occurs.

Cognitive Effects—Cognitive adverse reactions can occur in patients receiving AYVAKIT and occurred in 7.8% of patients with ISM who received AYVAKIT + best supportive care (BSC) versus 7.0% of patients who received placebo + BSC; <1% were Grade 3. Depending on the severity, withhold AYVAKIT and then resume at the same dose, or permanently discontinue AYVAKIT.

Photosensitivity—AYVAKIT may cause photosensitivity reactions. In all patients treated with AYVAKIT in clinical trials (n=1049), photosensitivity reactions occurred in 2.5% of patients. Advise patients to limit direct ultraviolet exposure during treatment with AYVAKIT and for one week after discontinuation of treatment.

Embryo-Fetal Toxicity—AYVAKIT can cause fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females and males of reproductive potential to use an effective contraception during treatment with AYVAKIT and for 6 weeks after the final dose. Advise women not to breastfeed during treatment with AYVAKIT and for 2 weeks following the final dose.

Adverse Reactions—The most common adverse reactions (≥10%) in patients with ISM were eye edema, dizziness, peripheral edema, and flushing.

Drug Interactions—Avoid coadministration of AYVAKIT with strong or moderate CYP3A inhibitors or inducers.

To report suspected adverse reactions, contact Blueprint Medicines Corporation at 1-888-258-7768 or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Please click here to see the full Prescribing Information for AYVAKIT.

References:

  1. AYVAKIT [prescribing information]. Cambridge, MA: Blueprint Medicines Corporation; May 2023.
  2. Kristensen T et al. Am J Hematol. 2014;89(5):493-498.
  3. Garcia-Montero AC et al. Blood. 2006;108(7):2366-2372.
  4. Ungerstedt J et al. Cancers. 2022;14(16):3942.
  5. Pardanani A. Am J Hematol. 2023;98(7):1097-1116.
  6. Data on file. Blueprint Medicines Corporation, Cambridge, MA. 2023.
  7. Gülen T et al. J Intern Med. 2016;279(3):211-228.
  8. Theoharides TC et al. N Engl J Med. 2015;373(2):163-172.
  9. Gotlib J et al. NEJM Evidence. 2023;2(6). Published online May 23, 2023. doi:10.1056/EVIDoa2200339
  10. Padilla B et al. Orphanet J Rare Dis. 2021;16(1):434.